Drug Pipeline & Clinical Update - April 2026

Judi Health closely monitors the drug landscape to provide ourclients with timely information on newly FDA approved medications and productsin the pipeline. Please find the April2026 Monthly Drug Update below:

Key New Drug Approvals

Lifyorli™ (relacorilant) oral capsule

Approval Date: 03/25/2026

Indication: Treatment, in combination with nab-paclitaxel, of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have received one to three prior systemic treatments, at least one of which included bevacizumab.

Cost*: TBD

Key Consideration:

• The first FDA-approved selective glucocorticoid receptor antagonist (SGRA)

Press Release: FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

‍

Foundayo^TM (orforglipron) oral tablet

Approval Date: 04/01/2026

Indication: Chronic weight management, in combination with a reduced-calorie diet and increased physical activity, in adults with obesity or overweight who have at least one weight-related comorbid condition.

Cost*: TBD

Key Consideration:

• Once daily oral tablet, taken with or without food
• Dosage starts at 0.5 mg daily and can be increased after at least 30 days

Press Release: FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

‍

Idvynso^TM (doravirine; islatravir) oral tablet

Approval Date: 04/20/2026

Indication: Treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.

Cost*: $4,455 per month

Key Consideration:

• Once daily, two drug (doravirine: nonnucleoside reverse transcriptase inhibitor (NNRTI); islatravir: nucleoside analog reverse transcriptase inhibitor (NRTI)) single tablet regimen

Press Release: FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)

‍

Notable Expanded Indications

• Neffy® (epinephrine) – expanded to treat type I allergic reactions, including anaphylaxis, in patients who weigh 15 kg or greater
• Licart® (diclofenac) – expanded to treat acute pain due to minor strains, sprains, and contusions in patients 6 years and older
• Filspari® (sparsentan) – expanded to reduce proteinuria in patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome
• Breztri® Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) – expanded to treat asthma in patients 12 years of age and older
• Dupixent® (dupilumab) – expanded to treat patients aged 2 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment

‍

Generic Launches

• Farxiga® (dapagliflozin) oral tablet
• Xigduo XR® (dapagliflozin/metformin) oral tablet
• Lumigan® (bimatoprost) ophthalmic solution
• Ofev® (nintedanib) oral capsule

‍

*Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support